Können Inkretin-Mimetika den Beginn der Insulintherapie hinauszögern?
Können Inkretin-Mimetika den Beginn der Insulintherapie hinauszögern?
复制标题
DOI：
10.1007/bf03365101
复制
发表时间：
2007-06
期刊：
影响因子：
--
通讯作者：
K. Parhofer
中科院分区：
文献类型：
--
作者：
K. Parhofer
GLP-1受体激动剂（如艾塞那肽）是一组模拟肠促胰岛素激素GLP-1的新型治疗药物。这些药物刺激胰岛素分泌，同时抑制胰高血糖素分泌，抑制胃运动，降低食欲，从而减少食物摄入。这组药物还诱导空腹和餐后血糖浓度、HbA 1c降低，并最终导致体重减轻。这些药物皮下给药（exenetrine每日两次）。最常见的副作用是轻微的恶心。虽然短期研究是有希望的，但需要长期临床研究来确定这种方法治疗2型糖尿病的益处。
GLP-1 receptor agonists such as exenatide are a group of new therapeutic agents that mimic the gut-derived incretin hormone GLP-1. These drugs stimulate insulin secretion while suppressing glucagon secretion, inhibit gastric motility, reduce appetite and hence, food intake. This group of drugs also induce reduction in fasting and postprandial glucose concentrations, HbA1c and ultimately lead to weight loss. The drugs are administered subcutaneously (exenatide twice daily). The most common side effect is mild nausea. Although short-term studies are promising, long-term clinical studies are needed to determine the benefits of this approach for the treatment of type 2 diabetes.